

Profiling the plasmid conjugation potential of urinary *Escherichia coli*

Cesar Montelongo Hernandez¹, Catherine Putonti^{2,3} and Alan J. Wolfe^{1,*}

Abstract

Escherichia coli is often associated with urinary tract infection (UTI). Antibiotic resistance in *E. coli* is an ongoing challenge in managing UTI. Extrachromosomal elements – plasmids – are vectors for clinically relevant traits, such as antibiotic resistance, with conjugation being one of the main methods for horizontal propagation of plasmids in bacterial populations. Targeting of conjugation components has been proposed as a strategy to curb the spread of plasmid-borne antibiotic resistance. Understanding the types of conjugative systems present in urinary *E. coli* isolates is fundamental to assessing the viability of this strategy. In this study, we profile two well-studied conjugation systems (F-type and P-type) in the draft genomes of 65 urinary isolates of *E. coli* obtained from the bladder urine of adult women with and without UTI-like symptoms. Most of these isolates contained plasmids and we found that conjugation genes were abundant/ubiquitous, diverse and often associated with IncF plasmids. To validate conjugation of these urinary plasmids, the plasmids from two urinary isolates, UMB1223 (predicted to have F-type genes) and UMB1284 (predicted to have P-type genes), were transferred by conjugation into the K-12 *E. coli* strain MG1655. Overall, the findings of this study support the notion that care should be taken in targeting any individual component of a urinary *E. coli* isolate's conjugation system, given the inherent mechanistic redundancy, gene diversity and different types of conjugation systems in this population.

DATA SUMMARY

This study uses the urinary *E. coli* isolates, sequence reads, and contigs first published in Garretto et al. 2020 (Table S1). Assembled whole genome sequences (WGS) for these isolates were downloaded from NCBI BioProject PRJNA316969. Raw sequence reads for transconjugant K-12 respectively carrying pU1223 (SRR15011177) and pU1284 (SRR15011176) were submitted to GenBank.

INTRODUCTION

Escherichia coli is linked to urinary tract infection (UTI) [1–3]. Because the key genetic determinants of *E. coli* pathogenicity in the urinary tract remain unknown, management is a challenge [4–6]. This clinical dilemma is compounded by antibiotic resistance [7, 8]. Genes that encode antibiotic resistance are often carried by plasmids, genetic elements that can propagate and retain genes not only for resistance but also for virulence and fitness [8–10]. Due to their variable genetic composition, plasmids can be classified by incompatibility (*inc*) grouping, which denotes the inability of two plasmids to be maintained in the same host [11–13]. A prime example of clinically relevant plasmids in *E. coli* are the F plasmids, characterized by the *inc* loci *incFI* and/or *incFII* [14, 15]. F plasmids are widespread, heterogeneous, stable and generally mobile [8, 10, 16]. F plasmids have frequently been found in urinary *E. coli*, specifically in extended-spectrum β -lactamase (ESBL)-producing *E. coli* isolated from urinary infection [17]. Also, the uropathogenic *E. coli* (UPEC) strain UTI89 harbours an F plasmid hybrid – pUTI89 – and its loss results in a significant decrease in pathogenicity in a mouse model during early infection [18]. The pUTI89 plasmid has been noted to carry pathogenesis genes in addition to a conjugation system, which is key for plasmid mobility [6, 16, 19].

Received 04 July 2021; Accepted 16 March 2022; Published 10 May 2022

Author affiliations: ¹Department of Microbiology and Immunology, Stritch School of Medicine, Loyola University Chicago, Maywood, IL 60153, USA;

²Bioinformatics Program, Loyola University Chicago, Chicago, IL 60660, USA; ³Department of Biology, Loyola University Chicago, Chicago, IL 60660, USA.

***Correspondence:** Alan J. Wolfe, awolfe@luc.edu

Keywords: conjugation; *Escherichia coli*; genome; incompatibility group; plasmids; urinary tract.

Abbreviations: NCBI, National Center for Biotechnology Information; T4SS, type IV secretion system; UTI, urinary tract infection.

Data statement: All supporting data, code and protocols have been provided within the article or through supplementary data files. Nine supplementary tables are available with the online version of this article.

000814 © 2022 The Authors



This is an open-access article distributed under the terms of the Creative Commons Attribution License.

Impact Statement

In this study, we sought extrachromosomal elements – plasmids – in the draft genomes of 65 *Escherichia coli* strains isolated from bladder urine of adult women with and without urinary tract infection-like symptoms. We profiled conjugation systems that *E. coli* uses to transfer genes between cells. We performed this analysis because others had proposed to target conjugation components as a strategy to curb the spread of plasmid-borne antibiotic resistance. Our findings suggest caution in targeting any individual component of a urinary *E. coli* isolate's conjugation system, given the inherent mechanistic redundancy, gene diversity, and different types of conjugation systems in this population.

Conjugation is the cell-to-cell translocation of genetic information assisted by conjugative machinery – conjugative pilus, DNA processing enzymes (relaxosome), mating pair stabilization proteins and the type IV secretion system (T4SS) [16, 20]. The prototypical conjugation system in *E. coli* is the F-type system, which uses transfer (*tra*) genes [10, 21, 22]. The transfer operon is composed of genes that are considered to be essential for conjugation (*traA*, *traB*, *traK*, *traC*, *traW*, *trbC*, *traE*, *traL*, *traH*, *traG*, *traU*, *traI*, *traM*, *traD*) for F plasmid transfer and, in some cases, more than a dozen accessory genes [19, 20, 22]. Because expressing conjugation machinery is an expensive endeavour, it is repressed by the fertility inhibition (FinOP) system that targets the transcription regulator TraJ [23]. TraJ upregulates the transfer operon, resulting in the expression of components involved in forming the relaxosome (*traD*, *traI*, *traM*, *traY*), conjugative pilus (*traP*, *traE*, *traL*, *traC*, *traW*, *trbC*, *traF*, *trbB*), mating pair stabilization (*traN*, *traG*, *traU*) and T4SS core proteins (*traB*, *traK*, *traV*) [16, 20, 21, 23]. The transfer operon also can encode proteins that defend against excessive conjugation with the same or similar plasmids, either by surface exclusion (TraT) or entry exclusion (TraS) [23, 24]. F plasmids are the typical group associated with the F-type conjugation system [16].

Functional and structural relatives of the F-type transfer system exist, such as the P-type VirB/VirD4 system, which also utilizes a T4SS for conjugation and has been extensively studied in *Agrobacterium tumefaciens* [16, 20, 25]. Components consist of the type IV coupling protein (VirD4), inner membrane complex (VirB4), outer membrane complex (VirB7, VirB9, VirB10), conjugative pilus (VirB2 pilin), transglycosylase (VirB1) and pilus-tip protein (VirB5) [16, 26]. The plasmids RP4, R388 and pKM101 are well-studied *E. coli* plasmids associated with a P-type system [27–29]. The VirB/VirD4 system has been implicated not just in intra-species genetic exchange, but also in inter-species and even inter-kingdom conjugation [30, 31]. Likely due to the constant genetic exchange in plasmids that results in genomic heterogeneity, bacteria may carry plasmids that borrow components from different conjugation systems [16, 25].

Conjugation is a potential target in curtailing the spread of antibiotic resistance in the clinical setting [26, 32]. Hypothetically, blocking key transfer functions by conjugation inhibitors (COINs) could decrease plasmid exchange and, by extension, decrease propagation of bacterial genes for antibiotic resistance, virulence and fitness [33–37]. It has been noted that COINs should ideally not inhibit bacterial growth and be used in conjunction with antibiotics [32]. However, deployment of such a strategy requires further considerations [26, 32]. Outside of identifying genes essential for conjugation and determining how to mechanistically target them, we must know how a particular bacterial population depends on a given conjugation system. Targeting a conjugation component would be less effective if this factor was not abundant in a population or if this factor could be replaced by another component. Furthermore, if there were multiple distinct conjugation systems in a population, the targeting of one system might simply lead to the selection and propagation of the other [38, 39]. In considering conjugation as a viable target for inhibition in the clinical setting, we must first understand in more detail the conjugation systems in clinical bacterial isolates in a given niche.

In this study, we profile F-type and P-type conjugation genes in 65 urinary *E. coli* isolated from catheterized bladder urine of adult women with or without UTI-like symptoms [5]. Plasmids were present in 84.6% ($N=55/65$) of urinary *E. coli* isolates, and the majority included F-type conjugation genes with the minority having the P-type conjugation genes. To validate conjugation of these urinary plasmids and viability of the F-type and P-type systems, we transferred by conjugation the plasmids from two isolates, UMB1223, which has F-type genes, and UMB1284, which has P-type genes, into the *E. coli* K-12 strain MG1655. Multiple types of conjugation loci exist in urinary *E. coli*. Overall, our investigation finds that conjugation systems are common in urinary *E. coli* and that conjugation genes are diverse in number and composition. This knowledge is important to understanding conjugation in the clinical setting and how this process may be targeted.

METHODS

This study uses the urinary *E. coli* isolates, sequence reads and contigs first published by Garretto *et al.* in 2020 (Table S1, available with the online version of this article) [5]. These isolates were recovered from urine samples collected from adult women with and without UTI-like symptoms via transurethral catheterization during several Institutional Review Board-approved studies at Loyola University Chicago (USA) (LU203986, LU205650, LU206449, LU206469, LU207102 and LU207152) and the University

of California San Diego (USA) (170077AW). Assembled whole-genome sequences (WGSs) for these isolates were downloaded from National Center for Biotechnology Information (NCBI) BioProject PRJNA316969.

To identify known plasmid *inc* loci, *E. coli* WGS FASTA files were scanned using PlasmidFinder v2.1 (<https://cge.cbs.dtu.dk/services/PlasmidFinder/>) using the *Enterobacteriaceae* database with a threshold of 95% identity and a minimum 60% coverage (Table S2) [13]. The genomes were binned into a plasmid group associated with their *inc* genes via exclusion criteria: genomes with *incF* genes were placed in the IncF group, genomes with *col* but no *incF* genes were placed in the Col group, and genomes with *inc* genes that were neither *incF* nor *col inc* genes were in the Inc-various group. The *E. coli* plasmid literature was reviewed for genes used in plasmid conjugation, primarily from the F-type transfer and P-type VirB-VirD4 systems (Tables S3 and S4) [20, 23]. NCBI Local BLAST v2.11.0 was used to query this initial set of conjugation genes in the 65 urinary *E. coli* draft genomes [40, 41].

Conjugation was utilized as the method to transfer plasmids from urinary *E. coli* isolates to a laboratory *E. coli* K-12 strain (MG1655 with a chloramphenicol-resistance cassette) that possessed a chloramphenicol selection marker [42]. To attempt conjugation, we searched for compatible antibiotic-resistance traits in urinary isolates (potential conjugation donors), CamS and resistance to one of the following: kanamycin, spectinomycin, tetracycline, ampicillin. Urinary *E. coli* isolates with identified plasmids, the appropriate resistance markers and carrying transfer genes were grown on various antibiotic plates to assess their selection marker profile. Lysogeny broth (LB) agar plates (1.0% bacto tryptone, 1.0% yeast extract, 0.5% NaCl, 1.5% agar) were supplemented with these respective antibiotics: ampicillin (Amp, 100 µg ml⁻¹), chloramphenicol (Cam, 25 µg ml⁻¹), kanamycin (Kan, 40 µg ml⁻¹), spectinomycin (Spec, 100 µg ml⁻¹) or tetracycline (Tet, 15 µg ml⁻¹) (Table S5). Isolates that grew on an antibiotic had their sequences reviewed for antibiotic-resistance genes in their contigs, which also were compared to plasmid entries in the NCBI nr/nt database. Urinary *E. coli* plasmid donor candidates were filtered on the following basis: they could grow on an antibiotic selection marker, they carried a gene that was predicted to encode antibiotic resistance, this resistance gene was on a predicted plasmid, and they had evidence of near complete F-type or P-type operons (Table S6) [16].

Two urinary *E. coli* (UMB1223, UMB1284) met the criteria and were used as plasmid donors; UMB0939 was used as a negative control, as it met all the criteria except identifiable conjugation genes. Conjugation in *E. coli* was performed as described elsewhere (Table S6) [42]. K-12 transconjugants carrying the urinary plasmids were able to grow on double chloramphenicol and tetracycline LB agar plates. For DNA extraction, bacteria were grown as liquid cultures in LB (with chloramphenicol and tetracycline as selection markers) at 37 °C in a shaking incubator for 12 h. Whole-genome DNA was extracted using a Qiagen DNeasy UltraClean microbial kit using the manufacturer's standard protocol. Plasmid DNA was extracted using a Qiagen large-construct kit using the manufacturer's standard protocol. A Qubit fluorometer was used to quantify the DNA concentration in the obtained genomic and plasmid DNA preparations. Nextera XT DNA library preparation kit was used to make DNA libraries, which were sequenced on the Illumina MiSeq platform using the MiSeq reagent kit v2 (500 cycles) at the Loyola University Chicago's Genomics Facility (Maywood, IL, USA). Raw sequence reads for transconjugant K-12 respectively carrying pU1223 (accession no. SRR15011177) and pU1284 (accession no. SRR15011176) were submitted to GenBank. The raw sequence reads from the whole-genome extraction were assembled using plasmidspades.py of SPAdes v3.12 with *k* values of 55, 77, 99, 127 and the only-assembler parameter [43]. Assemblies were renamed via a bash script and contigs less than 500 bp were removed via Bioawk. Plasmidic assemblies were queried against the nr/nt database via NCBI's web BLAST and hits were binned as either *E. coli* plasmid or chromosome [40, 41]. A curated plasmidic assembly was made using only contig hits to plasmid sequences by pruning contigs with homology to chromosomal entries in the nr/nt database.

NCBI Local BLAST v2.11.0 was used to query conjugation genes, as described above, in the plasmidic assemblies for plasmids pU1223 and pU1284 [40, 41]. pU0928 and pU1284 were annotated via Prokka v1.13.5 and the location of F-type and P-type conjugation genes was identified using the genome viewer function of Geneious Prime v2021.1prokk [44, 45]. Predicted genes in these loci were queried against the NCBI nr/nt collection via BLAST [40, 41]. Conjugation genes in pU1223 and pU1284 not included in our initial query list were concatenated into a new query list and all 65 urinary *E. coli* draft genomes were queried for these additional genes. Hits with a query coverage over 85% and sequence identity over 90% were recorded as present. We designated these parameters to have a high homology threshold while accounting for reported variable regions in conjugation genes [20]. The proportion of all genes queried, including those in the initial scan and those newly identified in pU1223 and pU1284, was calculated for all urinary *E. coli* genomes.

RESULTS

Sixty-five urinary *E. coli* draft genomes were queried by PlasmidSPAdes to identify plasmid *inc* genes (Table S2). These 65 strains were isolated by our team via catheterization and, thus, are members of the bladder microbiota, which differs from the urethral microbiota [46] that is also present in voided urine samples. For each genome sequence, we also have symptom data from the participant. To facilitate plasmid group analyses, we binned isolates with *incF* genes into the IncF group, isolates with *col* genes but no *incF* genes in the Col group, and isolates with *inc* genes that were neither *incF* nor *col* into the Inc-various group. We performed an initial query utilizing F-type and P-type genes on the 65 urinary *E. coli* draft genomes (genes queried are listed in Tables S3 and S4) [16, 20]. Genes previously associated with F plasmid transfer, most notably




Fig. 1. F transfer genes in sequences with evidence of an F-type system. Transfer genes were identified in urinary *E. coli* genomes. Genomes with evidence of an F-type system were further analysed for the presence of transfer genes required for conjugation and, thus, which could most likely succeed in transferring their plasmid by conjugation to *E. coli* K-12.

tra genes, were in relatively high proportion in draft genomes with F-type genes (Fig. 1). To validate plasmid conjugation in these isolates, we respectively chose two urinary *E. coli* isolate predicted to have a F-type system (UMB1223) and P-type system (UMB1284) [16]. UMB1223 and UMB1284 could grow on tetracycline plates and their tetracycline-resistance gene was localized to a putative plasmid sequence within the genome assembly (Table S5). Our initial gene query utilizing reference conjugation genes indicated that UMB1223 had 23 *tra* genes in a putative plasmid sequence, while UMB1284 had 5 *virB* genes in addition to 2 *tra* genes (Table S6). To confirm conjugation, the genetic content in the MG1655 transconjugants was extracted, sequenced and submitted to GenBank (K-12 with plasmid from UMB1223 under accession no. SRR15011177, K-12 with plasmid from UMB1284 under accession no. SRR15011176). The raw sequence reads were assembled into plasmid contigs (pU1223 and pU1284, respectively) and analysed. We verified the presence of a tetracycline-resistance cassette, *incF* loci and conjugation genes like those present in the original (donor) urinary isolates (compare Table 1 to Table S6).

We reviewed the contigs in pU1223 and pU1284 for the presence of conjugation loci, including genes we may not have identified in our initial query using conjugation gene references (Tables S3 and S4). The conjugation locus in pU1223 consisted of 39 ORFs that included the transfer genes we had profiled in the parent isolate UMB1223; it also included variants of transfer genes not initially identified, two transposons and four hypothetical genes (Fig. 2, Table S7). The transfer locus was organized in the prototypical manner of a F-type transfer operon, with *finO* upstream and both *traJ* and *traM* downstream of the rest of the *tra* genes, plus the presence of all *tra* genes essential for conjugative transfer [20, 21]. The operon contained 17 non-essential transfer genes, in addition to two transposon sequences mid-operon, plus four hypothetical (HP) coding regions flanked by transfer genes. *HP_1* was 109 amino acids long and was not homologous to any entries in the NCBI database or known protein domains. *HP_2* had some homology to the neighbouring *traC*, while *HP_3* and *HP_4* had homology to the neighbouring *traJ*. Seven of the transfer genes identified in pU1223 were variants of the reference sequences we initially used to carry out the profile and were not initially identified because they failed to meet our threshold relative to the queries used; all these variants had high homology to transfer genes in GenBank (Table S7). pU1284 contained the P-type *virB-virD4* operon in one contig and a locus with F-type genes in another contig (Fig. 2). Except for *virB3* and *virB7*, pU1284 had all VirB-VirD4 genes in the same locus with a prototypical sequential organization (Table S8). Some of the *vir* components missed in our initial profile were present in the operon as a variant of our initial query sequence. We also identified three novel genes with T4SS homology upstream of *virD4*, between *virB6* and *virB5*. These T4SS ORFs had high sequence identity

Table 1. Overview of urinary plasmids sequenced from *E. coli* K-12 transconjugants

Background strain	Urinary <i>E. coli</i> plasmid donor	Urinary plasmid replicon	Tc resistance gene in plasmid	Conjugation genes identified
MG1655	UMB1223	<i>col156, incFIA, incFIB, incFII</i>	Yes	F-type
MG1655	UMB1284	<i>incFIA, incFII, incX</i>	Yes	P-type, F-type




Fig. 2. Conjugation gene operons in the plasmids conjugated to an *E. coli* K-12 strain from UMB1223 and UMB1284. Plasmidic contigs were assembled from the raw sequencing reads of *E. coli* K-12 strain MG1655 carrying a plasmid from either UMB1223 or UMB1284. Contigs containing hits to conjugation genes were identified. (a) pU1223 had a 39 gene operon containing *tra* and *trb* genes, in addition to two transposons (*Tnp*). (b) pU1284 had an operon containing *vir* genes in one contig, including three unknown genes with homology to a T4SS and a hypothetical gene. (c) In addition, pU1284 had a locus of *tra* genes in another contig, including a hypothetical gene.

and query coverage to entries associated with conjugative and T4SS function in GenBank (Table S8). T4SS_1 had a conjugal protein domain (PRK13893, pfam07424) like that in TrbM. T4SS_2 had protein domains of the Cag pathogenicity island proteins (pfam13117). T4SS_3 had the TrbL protein domain associated with conjugal proteins, in addition to a VirB6-like domain and conjugal protein domain like that in TrbL (pfam04610, COG3704, PRK13875). A hypothetical gene (*hypo_vir*) was also found flanked by *virB8* and *virB6*, where the missing *virB7* is normally located. In addition to the *virB-virD4* operon, pU1284 had a locus in another contig with transfer genes including *traD*, *traT*, *traS*, *traG*, *traH* and a hypothetical ORF (*HP_5*) (Table S8). *HP_5* had no distinct homology to entries in the NCBI database, but was predicted to have multiple transmembrane domains.

We profiled all the urinary *E. coli* genomes using the newly identified ORFs in the putative conjugation regions from pU1223 and pU1284 (Fig. 3, Table S9). We estimated that plasmids are present in 84.6% ($N=55/65$) of these urinary *E. coli* isolates; most draft genomes had *incF* genes (81.8%, $N=45/55$). F-type conjugation genes were present in 72.7% of plasmids ($N=40/55$), all but one had *incF* genes (Table S9). No conjugation genes were predicted in the genomes from the Col group (Table S9). One urinary *E. coli* draft genome from the Inc-various group had 28 *tra* genes (Table S9). Urinary *E. coli* with no *inc* gene hits did not have F-type nor P-type conjugations genes (Table S9). Nearly all F-type genes queried were present in draft genomes from the IncF group, with a mean gene hit count of 27.1 genes per genome (Fig. 3). Multiple sequence variants were identified for *traJ*, *traS* and *traY*. The genes *trbP*, *trwB*, *trwC* and *trwM* were not found in any of the urinary *E. coli* genomes (Table S9).

Type-P genes, consisting of the VirB-VirD4 system, were present in 18.2% ($N=10/55$) of the urinary *E. coli* isolates with putative plasmids (Table 2). Five genomes (UMB0931, UMB1284, UMB1727, UMB6721, UMB7431) were predicted to encode *vir* genes like those in pU1284, encompassing a near complete VirB-VirD4 operon. Urinary *E. coli* genomes with a near complete VirB-VirD4 operon (including pU1284) had the gene *incFII*. Except for UMB1348, draft genomes with a small number of P-type genes did not have the gene *incFII* but rather *incFI* (UMB6655, UMB6890) or *incX1* (UMB1228) (Table 2). Six urinary *E. coli* genomes (UMB0931, UMB1284, UMB1727, UMB6721, UMB7431, UMB6653) were predicted to encode the three novel T4SS-like ORFs.

DISCUSSION

Urinary *E. coli* are associated with UTI [1–4, 47, 48]. In urinary isolates of *E. coli*, virulence factors and antibiotic-resistance cassettes are often retained and transmitted by conjugal plasmids [10, 49]. F plasmids have been reported previously as present in the urinary tract, both in *E. coli* strains isolated from patients with UTI diagnoses and in an F-like plasmid hybrid in the uropathogenic *E. coli* (UPEC) strain UTI89 [6, 17, 18]. Here, we have examined a representative set of urinary *E. coli* genomes from the bladders of adult women with and without UTI symptoms, providing evidence and investigation of the plasmid conjugation genes.

Conjugation components have been considered as targets to decrease the spread of plasmid-borne traits in the clinical setting [26, 32]. For this strategy to be viable, we must understand the conjugation systems in the niche of interest. The urinary




Fig. 3. Proportion of *tra* genes in the urinary *E. coli* plasmid group. The urinary *E. coli* genomes were scanned for all F-type genes, including variants and newly identified genes in pU1223 and pU1284. Urinary *E. coli* isolates with *incF* loci had a higher proportion than other plasmid groups in nearly every gene tested.

plasmid pU1223 had the F-type conjugation system, the most common conjugation system in the collection of urinary *E. coli* examined here (Fig. 2, Tables S7 and S8). The conjugation operon in pU1223 had all genes deemed ‘essential’ in an F-type system, in addition to 17 accessory genes; however, not all of the other urinary *E. coli* draft genomes followed this pattern [16, 20]. While genes such as *traA*, *traH*, *traG*, *traI* and *traD* were detected in more than 90% of draft genomes with F-type genes, there was no single gene present in all these genomes (Figs 1 and 3). We could infer that even if we targeted one of these high proportion components, a minority of urinary *E. coli* could potentially be unaffected.

Plasmid pU1284 had two conjugation loci, one a *virB-virD4* operon and the other an F-type transfer locus (Fig. 2, Table S8). We identified VirB-VirD4 genes in ten urinary *E. coli* draft genomes (Tables 2 and S9). Broadly, these urinary *E. coli* isolates with P-type genes fell into two groups. Plasmids with the first group had a near complete VirB-VirD4 operon similar to pU1284; all of these urinary *E. coli* genomes had the *incFII* gene. The second group had VirB-VirD4 genes that differed from those in pU1284; all but one lacked the *incFII* gene (Table 2). Urinary *E. coli* plasmids with P-type genes may represent a conjugative plasmid subpopulation; within this subpopulation, there may be further subgroups (i.e. those like pU1284 and those unlike pU1284) [14, 38, 50]. The presence of a minority of plasmids with a P-type conjugation system presents a troublesome scenario for targeting conjugation in this niche [14]. If we employ antibiotics against F-type genes, potentially we indirectly favour the propagation of plasmids with the P-type system

Table 2. Urinary *E. coli* isolates with VirB–VirD4 genes

Strain	In-compatibility loci	T4SS	T4SS_2	virD4	virD4_2	virB11	virB11_2	virB10	virB10_2	virB9	virB9_2	virB8	virB7	virB6	virB6_2	T4SS_3	virB5	virB5	virB4	virB3	virB2	virB2_2	virB1	virB1_2
UMB0931	<i>incFIA</i> , <i>incFIB</i> , <i>incFII</i> , <i>incP1</i> , <i>incX4</i>	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
UMB1284	<i>incFIA</i> , <i>incFII</i> , <i>incX4</i>	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
UMB1727	<i>incFIB</i> , <i>incFII</i> , <i>incBO/K/Z</i> , <i>incX4</i>	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
UMB6721	<i>incFIB</i> , <i>col156</i> , <i>incBO/K/Z</i> , <i>incFII</i> , <i>incX4</i>	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
UMB7431	<i>incBO/K/Z</i> , <i>incFII</i> , <i>incX4</i>	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
UMB6653	<i>incFIB</i> , <i>col156</i> , <i>incBO/K/Z</i> , <i>incX4</i> , <i>incFII</i>	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
UMB6655	<i>col156</i> , <i>incFIB</i> , <i>incI2</i>						+																	
UMB1348	<i>incFIB</i> , <i>col156</i> , <i>incFII</i> , <i>incX1</i>									+														
UMB1228	<i>incX1</i>																							
UMB6890	<i>col156</i> , <i>incFIB</i> , <i>incI2</i>																							+

[32, 38]. Antibiotic use may have to be weighed with the risk that it will favour a subpopulation of organisms and potentially change the plasmid dynamics of the niche [38, 51].

A further layer to the diversity of conjugation systems in urinary *E. coli* is that pU1284 not only had a P-type operon, but also an F-type locus with the F-type conjugation genes *traD*, *traG* and *traH* involved in the relaxosome, mating pair stabilization and pilus retraction, respectively (Fig. 2, Table S8). The F-type locus also had *traT* and *traS*, both involved in exclusion of invading plasmids in surface and entry exclusion, respectively [24, 52]. In addition to UMB1284, five urinary *E. coli* (UMB0931, UMB1727, UMB6721, UMB6653 and UMB7431) had a VirB-VirD4 system and different combinations of F-type transfer genes (Tables 2 and S9). These combinations of P-type and F-type genes could be linked to different environmental and evolutionary histories in the urinary tract [14, 16, 53]. This mosaic structure also highlights how urinary *E. coli* plasmids, such as F plasmids, can be genetically promiscuous [14]. Even if we target a conjugation system, this could be neutralized by the re-shuffling of genetic content in these plasmids to generate mosaic conjugation loci.

An important factor to consider is that our urinary *E. coli* isolates were collected from the bladders of different participants [5]. Potentially, the diversity of conjugation genes in the urinary tract of a single person is much lower [54]. Notwithstanding, we postulate that whole-genome sequencing and conjugation gene profiling would be key to the use of antibiotics that target conjugation components, especially in combination with traditional antibiotics [32]. Plasmid genetic variation in patients presents its own challenges, however, as targeting a single conjugation component may only be effective in a subset of cases. Overall, our evidence supports the concept that conjugation systems are common in urinary *E. coli*, especially in genomes with *incF* genes, and that these genes are diverse in number and composition [10]. The F-type system is the most common, but a minority of urinary *E. coli* had evidence of a P-type system [16]. Furthermore, urinary *E. coli* like UMB1284 appear to have supplemented their P-type system with some F-type genes, including a plasmid exclusion gene.

Conjugation components have been proposed as targets to limit the spread of plasmid-borne traits, such as antibiotic resistance [26, 32]. Targeting of a specific conjugation component should be considered in the context of (i) how frequent is that component in the plasmid population, (ii) how vital that component is to the conjugation system, and (iii) whether another conjugation system in the population could be unscathed. Modularity and redundancy is inherent to conjugation systems in bacteria and targeting isolated components could be ineffective or worse negatively affect the patient [10, 14, 16]. For example, by deploying antibiotics that target the F-type system, we may inadvertently increase the frequency of P-type conjugation, which could alter plasmid and microbiome dynamics [32]. The presence of different conjugation systems, frequency of individual conjugation genes, and combinations of these genes require further attention, as they may be key to plasmid exchange in the urinary tract. Conjugation systems in clinical isolates must be well characterized as part of our efforts to restrict the spread of plasmid-borne antibiotic resistance.

Funding information

This study was funded by National Institutes of Health (NIH) grant R01DK104718 (A.J.W.).

Acknowledgements

We thank Tanya Sysoeva (University of Alabama – Huntsville, USA) for her critical review of our manuscript.

Conflicts of interest

A.J.W. discloses membership on the scientific board of directors for Urobiome Therapeutics and for Pathnostics. He also discloses research funding from Pathnostics.

REFERENCES

1. Foxman B. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. *Infect Dis Clin North Am* 2014;28:1–13.
2. Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. *Nat Rev Microbiol* 2015;13:269–284.
3. Ronald A. The etiology of urinary tract infection: traditional and emerging pathogens. *Am J Med* 2002;113 (Suppl. 1A):14S–19S.
4. Mao B-H, Chang Y-F, Scaria J, Chang C-C, Chou L-W, et al. Identification of *Escherichia coli* genes associated with urinary tract infections. *J Clin Microbiol* 2012;50:449–456.
5. Garretto A, Miller-Ensminger T, Ene A, Merchant Z, Shah A, et al. Genomic survey of *E. coli* from the bladders of women with and without lower urinary tract symptoms. *Front Microbiol* 2020;11:2094.
6. Chen SL, Hung C-S, Xu J, Reigstad CS, Magrini V, et al. Identification of genes subject to positive selection in uropathogenic strains of *Escherichia coli*: a comparative genomics approach. *Proc Natl Acad Sci USA* 2006;103:5977–5982.
7. Nielsen KL, Dynesen P, Larsen P, Frimodt-Møller N. Faecal *Escherichia coli* from patients with *E. coli* urinary tract infection and healthy controls who have never had a urinary tract infection. *J Med Microbiol* 2014;63:582–589.
8. Koraimann G. Spread and persistence of virulence and antibiotic resistance genes: a ride on the F plasmid conjugation module. *EcoSal Plus* 2018;8:ESP-0003-2018.
9. Steinig EJ, Duchene S, Robinson DA, Monecke S, Yokoyama M, et al. Evolution and global transmission of a multidrug-resistant, community-associated methicillin-resistant *Staphylococcus aureus* lineage from the Indian subcontinent. *mBio* 2019;10:e01105-19.
10. Stephens C, Arismendi T, Wright M, Hartman A, Gonzalez A, et al. F plasmids are the major carriers of antibiotic resistance genes in human-associated commensal *Escherichia coli*. *mSphere* 2020;5:e00709-20.
11. Mutai WC, Waiyaki PG, Kariuki S, Muigai AWT. Plasmid profiling and incompatibility grouping of multidrug resistant *Salmonella enterica* serovar Typhi isolates in Nairobi, Kenya. *BMC Res Notes* 2019;12:422.

12. Arredondo-Alonso S, Willems RJ, van Schaik W, Schürch AC. On the (im)possibility of reconstructing plasmids from whole-genome short-read sequencing data. *Microb Genom* 2017;3:e000128.
13. Carattoli A, Zankari E, García-Fernández A, Voldby Larsen M, Lund O, *et al.* *In silico* detection and typing of plasmids using PlasmidFinder and plasmid multilocus sequence typing. *Antimicrob Agents Chemother* 2014;58:3895–3903.
14. Osborn AM, da Silva Tatley FM, Steyn LM, Pickup RW, Saunders JR. Mosaic plasmids and mosaic replicons: evolutionary lessons from the analysis of genetic diversity in IncFII-related replicons. *Microbiology* 2000;146:2267–2275.
15. Yang Q-E, Sun J, Li L, Deng H, Liu B-T, *et al.* IncF plasmid diversity in multi-drug resistant *Escherichia coli* strains from animals in China. *Front Microbiol* 2015;6:964.
16. Christie PJ. The mosaic type IV secretion systems. *EcoSal Plus* 2016;7:ESP-0020-2015.
17. Brolund A, Franzén O, Melefors O, Tegmark-Wisell K, Sandegren L. Plasmidome-analysis of ESBL-producing *Escherichia coli* using conventional typing and high-throughput sequencing. *PLoS One* 2013;8:e65793.
18. Cusumano CK, Hung CS, Chen SL, Hultgren SJ. Virulence plasmid harbored by uropathogenic *Escherichia coli* functions in acute stages of pathogenesis. *Infect Immun* 2010;78:1457–1467.
19. Smillie C, Garcillán-Barcia MP, Francia MV, Rocha EPC, de la Cruz F. Mobility of plasmids. *Microbiol Mol Biol Rev* 2010;74:434–452.
20. Bragagnolo N, Rodriguez C, Samari-Kermani N, Fours A, Korouzhdehi M, *et al.* Protein dynamics in F-like bacterial conjugation. *Biomedicines* 2020;8:E362.
21. Fernandez-Lopez R, de Toro M, Moncalian G, Garcillan-Barcia MP, de la Cruz F. Comparative genomics of the conjugation region of F-like plasmids: five shades of F. *Front Mol Biosci* 2016;3:71.
22. Lawley TD, Klimke WA, Gubbins MJ, Frost LS. F factor conjugation is a true type IV secretion system. *FEMS Microbiol Lett* 2003;224:1–15.
23. Virolle C, Goldlust K, Djermoun S, Bigot S, Lesterlin C. Plasmid transfer by conjugation in gram-negative bacteria: from the cellular to the community level. *Genes* 2020;11:1239.
24. Achtman M, Kennedy N, Skurray R. Cell-cell interactions in conjugating *Escherichia coli*: role of traT protein in surface exclusion. *Proc Natl Acad Sci USA* 1977;74:5104–5108.
25. Alt-Mörbe J, Stryker JL, Fuqua C, Li PL, Farrand SK, *et al.* The conjugal transfer system of *Agrobacterium tumefaciens* octopine-type Ti plasmids is closely related to the transfer system of an IncP plasmid and distantly related to Ti plasmid vir genes. *J Bacteriol* 1996;178:4248–4257.
26. Cabezón E, de la Cruz F, Arechaga I. Conjugation inhibitors and their potential use to prevent dissemination of antibiotic resistance genes in bacteria. *Front Microbiol* 2017;8:2329.
27. Fronzes R, Schäfer E, Wang L, Saibil HR, Orlova EV, *et al.* Structure of a type IV secretion system core complex. *Science* 2009;323:266–268.
28. Chandran V, Fronzes R, Duquerroy S, Cronin N, Navaza J, *et al.* Structure of the outer membrane complex of a type IV secretion system. *Nature* 2009;462:1011–1015.
29. Low HH, Gubellini F, Rivera-Calzada A, Braun N, Connery S, *et al.* Structure of a type IV secretion system. *Nature* 2014;508:550–553.
30. Fronzes R, Christie PJ, Waksman G. The structural biology of type IV secretion systems. *Nat Rev Microbiol* 2009;7:703–714.
31. Zatyka M, Thomas CM. Control of genes for conjugative transfer of plasmids and other mobile elements. *FEMS Microbiol Rev* 1998;21:291–319.
32. Graf FE, Palm M, Warringer J, Farewell A. Inhibiting conjugation as a tool in the fight against antibiotic resistance. *Drug Dev Res* 2019;80:19–23.
33. Sayer JR, Walldén K, Pesnot T, Campbell F, Gane PJ, *et al.* 2- and 3-substituted imidazo[1,2-a]pyrazines as inhibitors of bacterial type IV secretion. *Bioorg Med Chem* 2014;22:6459–6470.
34. Shaffer CL, Good JAD, Kumar S, Krishnan KS, Gaddy JA, *et al.* Peptidomimetic small molecules disrupt type IV secretion system activity in diverse bacterial pathogens. *mBio* 2016;7:e00221-16.
35. Ripoll-Rozada J, García-Cazorla Y, Getino M, Machón C, Sanabria-Ríos D, *et al.* Type IV traffic ATPase TrwD as molecular target to inhibit bacterial conjugation. *Mol Microbiol* 2016;100:912–921.
36. Bikard D, Euler CW, Jiang W, Nussenzweig PM, Goldberg GW, *et al.* Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials. *Nat Biotechnol* 2014;32:1146–1150.
37. Garcillán-Barcia MP, Jurado P, González-Pérez B, Moncalián G, Fernández LA, *et al.* Conjugative transfer can be inhibited by blocking relaxase activity within recipient cells with intrabodies. *Mol Microbiol* 2007;63:404–416.
38. Arredondo-Alonso S, Top J, McNally A, Puranen S, Pesonen M, *et al.* Plasmids shaped the recent emergence of the major nosocomial pathogen *Enterococcus faecium*. *mBio* 2020;11:e03284-19.
39. Jalasvuori M, Friman V-P, Nieminen A, Bamford JKH, Buckling A. Bacteriophage selection against a plasmid-encoded sex apparatus leads to the loss of antibiotic-resistance plasmids. *Biol Lett* 2011;7:902–905.
40. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. *J Mol Biol* 1990;215:403–410.
41. Camacho C, Coulouris G, Avagyan V, Ma N, Papadopoulos J, *et al.* BLAST+: architecture and applications. *BMC Bioinformatics* 2009;10:421.
42. Barrick J. General conjugation protocol; 2020. <https://barricklab.org/wiki/bin/view/Lab/ProtocolsConjugation> [accessed 9 March 2021].
43. Antipov D, Hartwick N, Shen M, Raiko M, Lapidus A, *et al.* plasmidSPAdes: assembling plasmids from whole genome sequencing data. *Bioinformatics* 2016;32:3380–3387.
44. Seemann T. Prokka: rapid prokaryotic genome annotation. *Bioinformatics* 2014;30:2068–2069.
45. Geneious. Geneious 2021.0.3; 2021. <https://www.geneious.com>
46. Chen YB, Hochstedler B, Pham TT, Acevedo-Alvarez M, Mueller ER, *et al.* The urethral microbiota: a missing link in the female urinary microbiota. *J Urol* 2020;204:303–309.
47. Yamamoto S, Tsukamoto T, Terai A, Kurazono H, Takeda Y, *et al.* Genetic evidence supporting the fecal-perineal-urethral hypothesis in cystitis caused by *Escherichia coli*. *J Urol* 1997;157:1127–1129.
48. Alteri CJ, Mobley HLT. Metabolism and fitness of urinary tract pathogens. *Microbiol Spectr* 2015;3:3.3.17.
49. Zagaglia C, Casalino M, Colonna B, Conti C, Calconi A, *et al.* Virulence plasmids of enteroinvasive *Escherichia coli* and *Shigella flexneri* integrate into a specific site on the host chromosome: integration greatly reduces expression of plasmid-carried virulence genes. *Infect Immun* 1991;59:792–799.
50. Wagner S, Lupolova N, Gally DL, Argyle SA. Convergence of plasmid architectures drives emergence of multi-drug resistance in a clonally diverse *Escherichia coli* population from a veterinary clinical care setting. *Vet Microbiol* 2017;211:6–14.
51. Tepekule B, Abel Zur Wiesch P, Kouyos RD, Bonhoeffer S. Quantifying the impact of treatment history on plasmid-mediated resistance evolution in human gut microbiota. *Proc Natl Acad Sci USA* 2019;116:23106–23116.
52. Sukupolvi S, O'Connor D. TraT lipoprotein, a plasmid-specified mediator of interactions between gram-negative bacteria and their environment. *Microbiol Rev* 1990;54:331–341.
53. Zienkiewicz M, Kern-Zdanowicz I, Gotebiewski M, Zylińska J, Mieczkowski P, *et al.* Mosaic structure of p1658/97, a 125-kilobase plasmid harboring an active amplicon with the extended-spectrum beta-lactamase gene blaSHV-5. *Antimicrob Agents Chemother* 2007;51:1164–1171.
54. Skyberg JA, Johnson TJ, Johnson JR, Clabots C, Logue CM, *et al.* Acquisition of avian pathogenic *Escherichia coli* plasmids by a commensal *E. coli* isolate enhances its abilities to kill chicken embryos, grow in human urine, and colonize the murine kidney. *Infect Immun* 2006;74:6287–6292.